WO2003077943A3 - Procede de fabrication d'une preparation pharmaceutique - Google Patents

Procede de fabrication d'une preparation pharmaceutique Download PDF

Info

Publication number
WO2003077943A3
WO2003077943A3 PCT/AT2003/000078 AT0300078W WO03077943A3 WO 2003077943 A3 WO2003077943 A3 WO 2003077943A3 AT 0300078 W AT0300078 W AT 0300078W WO 03077943 A3 WO03077943 A3 WO 03077943A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
aluminum compound
adsorption
production
poorly soluble
Prior art date
Application number
PCT/AT2003/000078
Other languages
German (de)
English (en)
Other versions
WO2003077943A2 (fr
Inventor
Hans Loibner
Erich Wasserbauer
Gottfried Himmler
Guenter Waxenecker
Original Assignee
Igeneon Krebs Immuntherapie
Hans Loibner
Erich Wasserbauer
Gottfried Himmler
Guenter Waxenecker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs Immuntherapie, Hans Loibner, Erich Wasserbauer, Gottfried Himmler, Guenter Waxenecker filed Critical Igeneon Krebs Immuntherapie
Priority to AU2003227073A priority Critical patent/AU2003227073A1/en
Publication of WO2003077943A2 publication Critical patent/WO2003077943A2/fr
Publication of WO2003077943A3 publication Critical patent/WO2003077943A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé de fabrication d'une préparation pharmaceutique par adsorption d'un agent actif dans un composé aluminium peu soluble. Le procédé selon l'invention est caractérisé en ce que l'agent actif est adsorbé dans un composé aluminium, nettoyé puis formulé en tant que préparation pharmaceutique
PCT/AT2003/000078 2002-03-20 2003-03-20 Procede de fabrication d'une preparation pharmaceutique WO2003077943A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003227073A AU2003227073A1 (en) 2002-03-20 2003-03-20 Method for the production of a pharmaceutical preparation by adsorption in a poorly soluble aluminum compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA427/2002 2002-03-20
AT4272002 2002-03-20

Publications (2)

Publication Number Publication Date
WO2003077943A2 WO2003077943A2 (fr) 2003-09-25
WO2003077943A3 true WO2003077943A3 (fr) 2004-01-15

Family

ID=27809065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2003/000078 WO2003077943A2 (fr) 2002-03-20 2003-03-20 Procede de fabrication d'une preparation pharmaceutique

Country Status (2)

Country Link
AU (1) AU2003227073A1 (fr)
WO (1) WO2003077943A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB960642A (en) * 1961-04-06 1964-06-10 Pfizer & Co C Measles vaccine
DE3150935A1 (de) * 1981-12-23 1983-06-30 Uwe Dr.med. 3400 Göttingen Böttcher Verfahren zur herstellung eines hepatitis-b impfstoffes
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB960642A (en) * 1961-04-06 1964-06-10 Pfizer & Co C Measles vaccine
DE3150935A1 (de) * 1981-12-23 1983-06-30 Uwe Dr.med. 3400 Göttingen Böttcher Verfahren zur herstellung eines hepatitis-b impfstoffes
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10

Also Published As

Publication number Publication date
AU2003227073A1 (en) 2003-09-29
WO2003077943A2 (fr) 2003-09-25
AU2003227073A8 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
IL163831A0 (en) Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
WO2007073911A3 (fr) Masquage de gout pour poudres
AU2003221604A1 (en) Use of an active substance that binds to cd28 for producing a pharmaceutical composition
WO2004037789A8 (fr) Derives de methylene uree
AU2003294879A1 (en) Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation
WO2001010816A3 (fr) Derives de 2-dialkylaminoalkylbiphenyle
WO2005079759A3 (fr) Composition pharmaceutique pour administration per os et mode de fabrication
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2003276054A1 (en) Method for the production of powdered active substance formulations by means of compressible fluids
AU2003223097A1 (en) Process for the preparation of concentrated solutions of stabilized hypobromites
WO2002030870A3 (fr) Derives de c-cyclohexylmethylamine substitues
WO2005023808A3 (fr) Synthèse
WO2007020448A3 (fr) Procede
WO2005020887A3 (fr) Methode de traitement du syndrome respiratoire aigu severe (sras) au moyen de composes de triptolide
WO2003089449A3 (fr) Composes aminoalkylsteroles avec activite anti-tumeur et neuroprotective
WO2003077943A3 (fr) Procede de fabrication d'une preparation pharmaceutique
AU2003294762A1 (en) Film-type preparations for transmucosal administration of nicotine and method for the production thereof
WO2004043900A3 (fr) Derives de 4-alkyl-/4-alcenyl-/4-alcynylmethyl-/1-aryl-cyclohexylamine
AU2003256102A1 (en) Method for the selective preparation of 3-oxo-4-aza-5a-androstane compound
AU2003225426A1 (en) Process for the preparation of urea
AU2002241277A1 (en) Functional plant, promoter to be used for producing the functional plant and method of using the same
AU2002229706A1 (en) Process for the fermentative production of d-pantothenic acid
AU2002232026A1 (en) Method for production of a pseudoboehmite adsorbing agent, the adsorbent product and its application
AU2003300018A1 (en) Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents
WO2003082189A3 (fr) Methode de production de pseudo-ilots

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 090552003

Country of ref document: AT

Date of ref document: 20030925

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 90552003

Country of ref document: AT

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP